Arrowhead Pharmaceuticals, Inc. (ARWR)
收市後：
Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
https://arrowheadpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 525
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Christopher R. Anzalone Ph.D. | CEO, President & Director | 1.6M | 5.26M | 1969 |
| Mr. Kenneth A. Myszkowski | Chief Financial Officer | 834.34k | 無 | 1966 |
| Mr. Patrick O'Brien J.D., PharmD | COO, General Counsel & Secretary | 835.14k | 990.4k | 1964 |
| Dr. James C. Hamilton M.D., MBA | Chief of Discovery & Translational Medicine | 762.14k | 無 | 1978 |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | 無 | 無 | 無 |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | 無 | 無 | 無 |
| Mr. Howard Lovy | Director of Communications | 無 | 無 | 無 |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist | 486.31k | 5.93M | 1954 |
| Dr. Mark Seefeld | Head of Toxicology & VP | 無 | 無 | 1954 |
| Ms. Tracie Oliver | Chief Commercial Officer | 449.58k | 無 | 1962 |
描述
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
公司管治
截至 2024年5月1日 止，Arrowhead Pharmaceuticals, Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：9；董事會：7；股東權利：1；現金賠償：2。
